Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Other Operating Expenses (2024 - 2025)

Caris Life Sciences has reported Other Operating Expenses over the past 2 years, most recently at $116.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 20.04% year-over-year to $116.1 million; the TTM value through Dec 2025 reached $433.4 million, changed N/A, while the annual FY2025 figure was $440.4 million, 14.06% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $116.1 million at Caris Life Sciences, up from $110.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $116.1 million in Q4 2025 and troughed at $94.0 million in Q3 2024.